HLA-DRB1∗15:01-DQA1∗01:02-DQB1∗06:02 haplotype protects autoantibody-positive relatives from type 1 diabetes throughout the stages of disease progression

Diabetes

Volumn 65, Issue 4, 2016, Pages 1109-1119

  Pugliese, Alberto ^a   Boulware, David ^a   Yu, Liping ^b   Babu, Sunanda ^b   Steck, Andrea K ^b   Becker, Dorothy ^c   Rodriguez, Henry ^d   Di Meglio, Linda ^e   Evans Molina, Carmella ^f   Harrison, Leonard C ^g   Schatz, Desmond ^h   Palmer, Jerry P ⁱ   Greenbaum, Carla ^j   Eisenbarth, George S ^b   Sosenko, Jay M ^a,k  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF COLORADO DENVER   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f INDIANA UNIVERSITY HEALTH   (United States)

^g INDIANA UNIVERSITY   (United States)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k BENAROYA RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUCOSE; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; HLA DQ ANTIGEN; HLA-DQA1 ANTIGEN; HLA-DQB1 ANTIGEN; HLA-DRB1*15:01 ANTIGEN;

ADULT; ARTICLE; AUTOIMMUNITY; CHROMOSOME; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HAPLOTYPE; HLA TYPING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; YOUNG ADULT; ADOLESCENT; BLOOD; CHILD; COMPLICATION; DIABETIC COMPLICATION; FAMILY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ADULT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-DQ ALPHA-CHAINS; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; MALE; RISK FACTORS; YOUNG ADULT;

EID: 84962137628     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1105     Document Type: Article

References (48)

1. Altmann DM, Trowsdale J. Major histocompatibility complex structure and function. Curr Opin Immunol 1989; 2:93-98
2. Thorsby E, Lie BA HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol 2005; 14: 175-182
3. Noble JA, Erlich HA Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2012; 2:a007732
4. Todd JA, Bell JI, McDevitt HO HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329: 599-604
5. Baisch JM, Weeks T, Giles R., Hoover M, Stastny P, Capra JD Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med 1990; 322:1836-1841
6. Morel PA, Dorman JS, Todd J.A., McDevitt HO, Trucco M. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc Natl Acad Sci U S A 1988; 85:8111-8115
7. ∗0602 allele in unaffected, islet cell antibody-positive first degree relatives and in rare patients with type 1 diabetes. J Clin Endocrinol Metab 1999; 84:1722-1778
8. ∗. J Clin Endocrinol Metab 2000; 85:3793-3797
9. Rønningen KS, Spurkland A, Tait BD, et al. HLA class II associations in insulin-dependent diabetes mellitus among Blacks, Caucasians, and Japanese. In HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference Held in Yokohoma, Japan, 6-13 November, 1991. Tsuji K, Aizawa M, Sasazuki T, Eds. Eds. Oxford University Press, 1993, p. 713-722
10. Pugliese A. Genetic protection from insulin-dependent diabetes mellitus. Diabetes Nutr Metab 1997; 10:169-179
11. Sorrentino R, De Grazia U, Buzzetti R, et al An explanation for the neutral effect of DR2 on IDDM susceptibility in central Italy. Diabetes 1992; 41:904-908
12. Carcassi C, Trucco G, Trucco M., Contu L. A new HLA-DR2 extended haplotype is involved in insulin-dependent diabetes mellitus susceptibility. Hum Immunol 1991; 31:159-164
13. Zeliszewski D, Tiercy JM, Boitard C, et al Extensive study of DRB, DQA, and DQB gene polymorphism in 23 DR2-positive, insulin-dependent diabetes mellitus patients. Hum Immunol 1992; 33:140-147
14. Erlich HA, Griffith RL, Bugawan T.L., Ziegler R., Alper C, Eisenbarth G. Implication of specific DQB1 alleles in genetic susceptibility and resistance by identification of IDDM siblings with novel HLA-DQB1 allele and unusual DR2 and DR1 haplotypes. Diabetes 1991; 40:478-481
15. Hoover ML, Marta RT Molecular modelling of HLA-DQ suggests a mechanism of resistance in type 1 diabetes. Scand J Immunol 1997; 45:193-202
16. ∗0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 1995; 44:608-613
17. ∗0602 allele. J Autoimmun 1996; 9:423-425
18. ∗0602: identification by the Diabetes Prevention Trial-Type 1. J Clin Endocrinol Metab 2000; 85:1255-1260
19. Redondo MJ, Babu S, Zeidler A., et al.; Diabetes Prevention Trial Type 1 Study Group. Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab 2006; 91:1705-1713
20. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009; 10:97-104
21. American Diabetes Association. Classification and diagnosis of diabetes, Sec. 2. In Standards of Medical Care in Diabetes - 2015. Diabetes Care 2015; 38(Suppl. 1):S8-S16
22. Sosenko JM, Skyler JS, Beam C.A., et al.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. Diabetes Care 2015; 38:940-942
23. Sosenko JM, Palmer JP, Rafkin L.E., et al.; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010; 33:620-625
24. Bonifacio E, Yu L, Williams A.K., et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases consortia. J Clin Endocrinol Metab 2010; 95:3360-3367
25. Vehik K, Beam CA, Mahon J.L., et al.; TrialNet Natural History Study Group. Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care 2011; 34:1897-1901
26. Wenzlau JM, Juhl K, Yu L., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104:17040-17045
27. Miao D, Guyer KM, Dong F, et al GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013; 62:4174-4178
28. Yu L, Dong F, Miao D., Fouts AR, Wenzlau JM, Steck AK. Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013; 36:2266-2270
29. Miao D, Steck AK, Zhang L, et al; Type 1 Diabetes TrialNet Study Group. Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technol Ther 2015; 17:119-127
30. ∗04 subtypes and type 1 diabetes. Ann N YAcad Sci 2003; 1005:301-309
31. Goel A, Chiu H, Felton J., Palmer JP, Brooks-Worrell B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes. Diabetes 2007; 56:2110-2115
32. Sosenko JM, Krischer JP, Palmer J.P., et al.; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibodypositive participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008; 31:528-533
33. Yu L, Boulware DC, Beam C.A., et al.; Type 1 Diabetes TrialNet Study Group. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012; 35:1213-1218
34. Ziegler AG, Rewers M, Simell O., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479
35. Williams AJ, Lampasona V, Wyatt R., et al. Reactivity to N-terminally truncated GAD65(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes. Diabetes 2015; 64:3247-3252
36. Williams AJ, Lampasona V, Schlosser M., et al.; Participating Laboratories. Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes. Diabetes 2015; 64:3239-3246
37. ∗0602 haplotype associated with attenuated protection from type 1 diabetes mellitus. Diabetologia 2005; 48:2540-2543
38. Schisterman EF, Cole SR, Platt RW Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009; 20:488-495
39. Pugliese A. The multiple origins of type 1 diabetes. Diabet Med 2013; 30: 135-146
40. Schmidt D, Verdaguer J, Averill N., Santamaria P. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. J Exp Med 1997; 186:1059-1075
41. Eerligh P, van Lummel M, Zaldumbide A, et al Functional consequences of HLA-DQ8 homozygosity versus heterozygosity for islet autoimmunity in type 1 diabetes. Genes Immun 2011; 12:415-427
42. Deng H, Apple R, Clare-Salzler M, et al. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease. J Exp Med 1993; 178: 1675-1680
43. Reichstetter S, Papadopoulos GK, Moustakas A.K., et al. Mutational analysis of critical residues determining antigen presentation and activation of HLA-DQ0602 restricted T-cell clones. Hum Immunol 2002; 63:185-193
44. ∗0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J Immunol 1998; 160:2365-2373
45. Harfouch-Hammoud E., Walk T, Otto H., et al. Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes 1999; 48:1937-1947
46. Astill TP, Ellis RJ, Arif S, Tree T.I., Peakman M. Promiscuous binding of proinsulin peptides to type 1 diabetes-permissive and - protective HLA class II molecules. Diabetologia 2003; 46:496-503
47. Miyadera H, Ohashi J, Lernmark Å, Kitamura T, Tokunaga K. Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. J Clin Invest 2015; 125:275-291
48. Insel RA, Dunne JL, Atkinson M.A., et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38:1964-1974